SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy
SIOUX FALLS, S.D., Nov. 08, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the company will be attending and presenting at this year’s , being held on Nov. 17-18 in Boston, MA. The Pharma Partnering Summit brings together dealmakers of leading life science companies to disseminate knowledge through expert speakers and help large, mid-sized and small pharma and biotech companies expand their network, establish deals, and develop their business.
SAB’s presentation, titled “Novel Biologic Therapeutics for Infectious Diseases,” will take place on Thursday, Nov. 17 at 12:25 pm ET. Led by SAB Co-Founder, President and Chief Executive Officer Eddie J. Sullivan, the presentation will focus on three therapeutics produced by SAB’s novel DiversitAb™ platform: SAB-176, a novel pan-influenza immunotherapeutic, SAB-195, an immunotherapeutic for Clostridioides difficile Infection (CDI or C. diff), and SAB-185, a broadly neutralizing COVID-19 treatment. Sullivan will also discuss how SAB’s platform is the only one in the world that produces fully-human polyclonal antibodies utilizing transchromosomic cows and how they can be efficacious against multiple variants of highly mutating pathogens.
“SAB is eager to join other industry pioneers at this summit, all of whom share the same goal of bringing better treatment options to the forefront of healthcare and improving patient’s lives,” Dr. Sullivan said. “Events like these are critical for the expansion of our network and the exchange of invaluable knowledge. We look forward to sharing how SAB’s innovative platform creates next-generation fully-human broadly neutralizing polyclonal antibody therapeutics that provide much more sustained efficacy in highly mutating pathogens and can offer much-needed support for immunocompromised patients.”
About SAB Biotherapeutics
SAB Biotherapeutics, Inc. (SAB) We are a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Our development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients. SAB has applied advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: and follow SAB on and .
Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our influenza program, C. diff. program, Type 1 Diabetes program, and other discovery programs, the likelihood that a patent will issue from any patent application, the results, including timing, of the development of SAB-176, SAB-185 and SAB-195 (including any IND filing or proposed clinical trials), financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government and other third-party collaborations or funded programs (including negotiations with the DoD). These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at . Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
Investor Relations:
Media Relations:
